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Abstract
Objective: Defects in ion channels and neurotransmitter receptors are impli-
cated in developmental and epileptic encephalopathy (DEE). Metabotropic glu-
tamate receptor 7 (mGluR7), encoded by GRM7, is a presynaptic G-protein-
coupled glutamate receptor critical for synaptic transmission. We previously
proposed GRM7 as a candidate disease gene in two families with neurodevelop-
mental disorders (NDDs). One additional family has been published since.
Here, we describe three additional families with GRM7 biallelic variants and
deeply characterize the associated clinical neurological and electrophysiological
phenotype and molecular data in 11 affected individuals from six unrelated
families. Methods: Exome sequencing and family-based rare variant analyses on
a cohort of 220 consanguineous families with NDDs revealed three families
with GRM7 biallelic variants; three additional families were identified through
literature search and collaboration with a clinical molecular laboratory. Results:
We compared the observed clinical features and variants of 11 affected individ-
uals from the six unrelated families. Identified novel deleterious variants
included two homozygous missense variants (c.2671G>A:p.Glu891Lys and
c.1973G>A:p.Arg685Gln) and one homozygous stop-gain variant (c.1975C>T:
p.Arg659Ter). Developmental delay, neonatal- or infantile-onset epilepsy, and
microcephaly were universal. Three individuals had hypothalamic–pituitary–axis
dysfunction without pituitary structural abnormality. Neuroimaging showed
cerebral atrophy and hypomyelination in a majority of cases. Two siblings
demonstrated progressive loss of myelination by 2 years in both and an
acquired microcephaly pattern in one. Five individuals died in early or late
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childhood. Conclusion: Detailed clinical characterization of 11 individuals from
six unrelated families demonstrates that rare biallelic GRM7 pathogenic variants
can cause DEEs, microcephaly, hypomyelination, and cerebral atrophy.
Introduction
Defects in ion channels and neurotransmitter receptors are
implicated in developmental and epileptic encephalopathies
(DEEs) by impairing central nervous system (CNS) neuro-
transmission.1,2 One such important group of receptors is
the glutamate receptors. Glutamate is an excitatory neuro-
transmitter that has been extensively studied in epilepsy and
that acts through two main receptor groups: ionotropic glu-
tamate receptors (iGluRs) and metabotropic glutamate
receptors (mGluRs).3 The iGluRs include N-methyl-D-as-
partate receptor (NMDAR), alpha-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor (AMPAR), and
kainate receptor (KAR). Rare monoallelic and biallelic single
nucleotide variants (SNVs) and copy number variants
(CNVs) in genes encoding postsynaptic iGluRs subunits
such as GRIN1, GRIN2A, GRIN2B, and GRIN2D encoding
the NR1, NR2A, NR2B, and NR2D subunits of NMDAR,
respectively, GRIA2-4 encoding the GluR2-4 subunits of
AMPAR, and GRIK2 encoding the GluR6 subunit of KAR
have been shown to cause a wide range of neurodevelop-
mental disorders (NDDs) and DEEs.4–11
The mGluRs consist of eight receptors, mGluRs1-8,
encoded by GRM1-8, that are classified into three groups
based on sequence homology, ligand selectivity, and signal
transduction mechanism.12 Group I consists of mGluR1
and mGluR5, group II consists of mGluR2 and mGluR3,
and group III consists of mGluR4, mGluR6, mGluR7, and
mGluR8. Groups II and III function presynaptically,
whereas group I functions postsynaptically.12 Recent stud-
ies have focused on the role of mGluRs in neurodevelop-
mental and neuropsychiatric disorders. A genome-wide
CNV study using single nucleotide polymorphism (SNP)
array revealed an enrichment of CNVs in GRM1, 5, 7, and 8
in subjects with attention deficit hyperactivity disorders
versus apparently healthy controls.13 Another pilot case–
control study supported an association between GRM7
SNPs and autism spectrum disorder.14 Biallelic rare vari-
ants in GRM1 have been shown to cause cerebellar ataxia.15
mGluRs are also involved in the pathophysiology of
epilepsy.16 Agonists of postsynaptic group I mGluRs have
proconvulsive properties while their antagonists have
anticonvulsant activity in seizure models, and the oppo-
site has been shown in the presynaptic mGluRs groups II
and III. These findings are attributed to the role of group
I mGluRs in enhancing neuronal excitability and of
groups II and III in inhibiting hyperexcitability.16
mGluR7, encoded by GRM7, is the most highly con-
served mGluR and is exclusively expressed in the CNS.
mGluR7 functions as a constitutional dimer and consists of
a binding domain, cysteine-rich domain, transmembrane
domain, and intracellular C-terminus.12 mGluR7 plays a
critical role in synaptic transmission by inhibiting further
release of excitatory neurotransmitter glutamate and
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inhibitory neurotransmitter GABA when they reach high
levels at the synapses.17 mGluR7-knockout mice develop
spontaneous stimulus-provoked seizures, suggesting that
disruption of GRM7 expression may cause epilepsy.18
We previously proposed GRM7 as a candidate gene for
autosomal recessive NDD in four subjects from two unre-
lated families with NDD and rare biallelic missense vari-
ants.19 One additional family including two siblings with
NDD and a rare homozygous stop-gain allele in GRM7
has been described since.20 Here, we describe five addi-
tional individuals from three unrelated families with bial-
lelic variants in GRM7 and a similar neurological DEE
phenotype along with the six individuals previously
reported with limited clinical data and provide evidence
to support GRM7 biallelic variants as a cause for NDDs,
DEE, and microcephaly.
Methods
Participants and ethical approval
This study was approved by the Institutional Review
Board (IRB) at Baylor College of Medicine under the
Baylor Hopkins Center for Mendelian Genomics Protocol
(IRB number H-29697). All families except for Family 3
(MR005) were enrolled under protocol H-29697. Family
3 (MR005) was enrolled under an IRB-approved protocol
at the University of Bonn (IRB number 033/08). For all
research subjects, informed patient consent was obtained
for publication of photographs.
Exome sequencing, linkage analysis, variant
interpretation, and phenotyping methods
By performing family-based exome sequencing and rare
variant filtering on a NDD cohort of 220 families from con-
sanguineous populations from Saudi Arabia and Turkey,
and using our previously described variant parsing and pri-
oritization workflow,21 we identified four individuals
(BAB6708, BAB6709, BAB10502, and BAB10517) from
three unrelated families (Families 1, 5, and 6 in Figs. 1 and 2)
with rare homozygousGRM7 variants.Comprehensive anal-
ysis of all exome sequencing data was performed to identify
rare, potentially damaging variants. No candidate variants
in known disease genes were identified in any of the four
individuals to provide an alternative genetic etiology.
Gene query to the Baylor Genetics diagnostic labora-
tory revealed five additional individuals (BAB8506,
brother of BAB8506, BAB13620, 2 brothers of BAB13620)
from two unrelated families (Families 2 and 4 in Figs. 1
and 2) with a similar neurological phenotype and delete-
rious biallelic GRM7 variants detected on proband exome
sequencing. Rudimentary clinical data were previously
published on four of these individuals (BAB6708,
BAB6709, BAB8506, and brother of BAB8506) from two
families (Family 1 and Family 2) as part of a cohort neu-
rological study.19 Two additional subjects from one family
(MR005, Family 3) were identified by literature search,
also published with limited phenotypic data in a gene dis-
covery cohort.20 Gene submission to GeneMatcher re-cap-
tured Family 3 (MR005).22
In Family 3 (MR005), linkage analysis and homozygos-
ity mapping were performed using HumanCytoSNP-12
BeadChip of all available members of the family (pro-
band, both parents, and five unaffected siblings) as
described in Abou Jamra et al. (2011).23 In total, five
regions of 1Mb or more (between 2.6 and 9.8 Mb, total
length of 24.6 Mb) with runs of homozygosity (ROH)
resulting in autozygosity were identified. Evaluation of
the variants was performed based on zygosity and locus
(in linkage regions) as previously described,24 coupled
with variant prevalence in public and private databases
and prediction models as described in the cases below.
All seven identified GRM7 variants were absent in the
homozygous state from public variant databases including
the Genome Aggregation Database (gnomAD), the Exome
Aggregation Consortium (ExAC), the Atherosclerosis Risk
in Communities Study Database (ARIC), and the
National Heart, Lung, and Blood Institute (NHLBI)
Grand Opportunity Exome Sequencing Project (ESP) as
well as from our in-house control database. The variants
were also absent in heterozygous and homozygous state
from the Iranome database (www.iranome.com) that con-
tains exomes of 100 healthy individuals from related eth-
nic groups.25 Three variants (RefSeq: NM_000844.4;
c.461T>C, c.1972C>T, and c.2024C>A) were entered by
our group into a public archive of human variation and
phenotypes (ClinVar) following the publication of the ini-
tial cohort (ClinVar accession numbers VCV000242895,
VCV000242900, and VCV000242901, respectively).21
Bioinformatic analyses (SIFT, PolyPhen2, MutationTaster,
CADD, and PhyloP) were used to predict the potential
deleterious or pathogenic effect of variants on protein
function and also evolutionary conservation. In four sub-
jects (Family 1 individuals II-1 and II-2, Family 5 individ-
ual II-1, and Family 6 individual II-1), absence of
heterozygosity (AOH) was determined based on the cal-
culated B-allele frequency from exome data using an in-
house developed bioinformatic tool, BafCalculator
(https://github.com/BCM-Lupskilab/BafCalculator), as
previously described.26 An arbitrary cutoff point or value
of 0.5 Mb was used in calculating the size of the AOH,
and unphased data or ROH block around the variant as
well as the total genomic AOH/ROH. In one subject
(Family 4 individual II-6), ROH was calculated from SNP
array data.
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Variants in all affected individuals, their parents, and
any available unaffected siblings were verified by Sanger
sequencing for segregation studies. Molecular diagnosis
was confirmed in 8 of the 11 affected individuals that
were alive at the time of the study, although all 11 sub-
jects were clinically examined during the course of their
illness for the features documented. Referring physicians
provided detailed clinical information and assessments on
all subjects for deep phenotyping. Updated clinical history
and clinical pictures were obtained on two of three previ-
ously published families (Families 1 and 2).19 Brain mag-
netic resonance images (MRIs) of eight individuals were
reviewed by a board-certified neuroradiologist (JVH).
Electroencephalograms (EEGs) of two individuals were
reviewed by a board-certified clinical neurophysiologist
(DM).
3D modeling of protein structure
3D protein structure of GRM7 was obtained from
SWISS-MODEL homology modeling server.27 This crystal
structure covers amino acids from 41 to 849. Protein
structure was displayed by the PyMol Molecular Graphics
System, v.1.5. Schrodinger, LLC. Amino acid conservation




We performed a comprehensive retrospective analysis of
patients’ clinical data including birth and perinatal
history, age of onset of disease, neurological features, sei-
zure types and response to treatment, growth parameters,
neurological exam findings as well as diagnostic studies
including EEGs and brain MRIs.
Basic clinical information and perinatal history of the
11 affected individuals from six unrelated families with
deleterious biallelic GRM7 variants are summarized in
Table 1. Subjects were from diverse ethnic backgrounds
and countries of origin including Saudi Arabia, Syria,
Turkey, United Arab Emirates, and the United States. All
individuals were born at term. Prominent perinatal com-
plications included neonatal intensive care unit (NICU)
admission for respiratory distress, apnea, desaturation or
neonatal seizures in five individuals (Family 1 individual
II-1, Family 2 individual II-2, and Family 4 individuals
II-1, II-4, and II-6), and polyhydramnios in four individ-
uals (Family 4 individuals II-1, II-4, and II-6 and Family
5 individual II-1). No history of perinatal insult was
found in any individuals. Birth weights were available in
nine individuals and were normal and within one stan-
dard deviation (SD) of the mean for age. Head circumfer-
ence measurement at birth was only available in one
subject (Family 2 individual II-2) and was also normal
while head circumference measurements at birth were not
available for the remaining subjects.
Neurological and other clinical features are detailed in
Table 2. Shared clinical features in all 11 subjects include
severe to profound global developmental delays (GDD),
intellectual disability (ID), and early-onset seizures within
the first year of life. Head circumference measurements at
time of last visit were available in eight individuals and
were consistent with microcephaly (3.8 to 2.7 SD
from mean for age). Review of the head circumference
Figure 1. Pedigrees, Sanger sequencing, facial features, and brain MRI images of affected individuals from Families 1–3 with biallelic variants in
GRM7. (A) Pedigree and Sanger sequencing showing segregation of the variants in GRM7 in Family 1. (B) Facial photograph of individual II-1
(Family 1) at 13 years showing prominent teeth and everted lower lip. (C-E) Brain MRI of individual II-1 (Family 1) at 3 years. T1-weighted image
(midsagittal view) shows moderate to severe thinning of corpus callosum (CC), excess cerebral spinal fluid (CSF) around the falx cerebri indicating
severe cerebral volume loss, and minimal cerebellar volume loss (C). T2-weighted images (axial and coronal views) show hypomyelination,
particularly over the anterior temporal horns, with normal fourth ventricle and hippocampi (D and E). (F) Facial photograph of individual II-2
(Family 1) at 10 years shows high forehead and hypotonic face (G-I) Brain MRI of individual II-2 (Family 1) at 2 years. T1-weighted image
(midsagittal view) showing foreshortening of CC, and excess CSF around the falx cerebri indicating severe cerebral volume loss (G). T2-weighted
images (axial and coronal views) show normally myelinated internal capsule, excessive subarachnoid spaces, enlarged lateral ventricles secondary
to cerebral volume loss, and T2 hyperintensity in bilateral hippocampi (H and I). (J) Pedigree and Sanger sequencing showing segregation of the
variants in GRM7 in Family 2. (K) Facial photograph of individual II-1 (Family 2) at 15 years shows a wide mouth. (L–N) Brain MRI of individual II-1
(Family 2) at 2 months. T1-weighted image (midsagittal view) shows normal CC (L). T2-weighted images (axial and coronal views) show normal
myelination for age (M and N). (O–Q) Brain MRI of individual II-1 (Family 2) at 7 years. T1-weighted image (midsagittal view) shows severe
thinning of CC and normal cerebellum (O). T2-weighted images (axial and coronal views) show global hypomyelination and normal hippocampus
(P and Q). (R) Facial photograph of individual II-2 (Family 2) at 10 years shows a wide mouth. (S–U) Brain MRI of individual II-2 (Family 2) at day
of life 2. T1-weighted image (midsagittal view) shows normal CC (S). T2-weighted images (axial and coronal views) show normal myelination for
age (T-U). (V-X) Brain MRI of individual II-2 (Family 2) at 5 years. T1-weighted image (midsagittal view) shows severe thinning and foreshortening
of CC, normal posterior pituitary and infundibulum, and normal vermis and cerebellum (V). T2-weighted images (axial and coronal views) show
global hypomyelination, small right cerebellar cyst and normal hippocampus (W and X). (Y) Pedigree and Sanger sequencing showing segregation
of the variants in GRM7 in Family 3. (Z) Facial features of individual II-6 (Family 3) at 6 years showing thick lips, crowded teeth, low frontal
hairline, remarkable nose, and bulbous nasal tip.
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chart from birth to current age in one individual (Family
2 individual II-2) revealed an acquired microcephaly pat-
tern with stagnation of head growth and crossing of cen-
tiles between 4 and 14 months (Fig. 3A and B). Other
common neurological features included axial hypotonia
(8/8), peripheral hypertonia (7/8), hyper-reflexia (4/6),
and drug-resistant epilepsy (6/9). Status epilepticus was
reported in four affected individuals (4/8). Additional
clinical features include failure to thrive (6/11), recurrent
infections (6/11), short stature (5/11), dysphagia (4/11),
and cortical visual impairment (3/11). Hormonal prob-
lems were present in 4/11 individuals in the form of pan-
hypopituitarism (1/11), growth hormone deficiency (1/
11), hypothyroidism (1/11), or unspecified hormonal
deficiency (1/11). Review of brain MRI images confirmed
the absence of a structural pituitary abnormality in 3/4 of
these subjects. The brain MRI images were not available
for review in the subject with the unspecific hormonal
deficiency. Occasionally reported medical problems
include iron or B12 deficiency anemia (3/11), lipodystro-
phy (2/11), and sensory or conductive hearing loss (2/11).
One subject had a nasogastric tube for feeding during
infancy due to poor feeding and evidence of aspiration
on modified barium swallow assessment. Self-mutilation
was reported in one subject. Four subjects died in infancy
or early childhood due to either aspiration pneumonia
(2/4), respiratory failure (1/4), or sudden infant death
syndrome (1/4), and one individual died in late child-
hood (at 13 years) from poor nutritional status and lack
of access to advanced medical care (Table 1).
Neuroimaging studies of 10 affected individuals are
summarized in Table 3, and representative images are dis-
played in Figures 1 and 2. Neuroimaging included brain
MRIs in nine subjects and a head CT in one additional
individual. Prominent neuroimaging findings included
cerebral atrophy (8/10) that ranged from mild (2/8) to
moderate/severe (6/8), global hypomyelination in 8/10
individuals, and moderate or severe thinning of corpus
callosum (CC) in 7/8. Additional findings included mild
cerebellar atrophy in 4/10 individuals, under-operculariza-
tion of the Sylvian fissures in 3/10, and hippocampal
atrophy or signal abnormality in 2/9, and brainstem vol-
ume loss in one individual (Family 4 individual II-6).
One subject (Family 4 individual II-6) had a compli-
cated medical course and developed hypoxic ischemic
encephalopathy (HIE) at age 3 years and 3 months fol-
lowing an aspiration event during oral feeding that led to
cardiac asystole and respiratory failure with return of cir-
culation after 30 min of cardiopulmonary resuscitation. A
brain MRI obtained 1 week following the aspiration event
showed interval worsening of the previously identified
cerebral volume loss and atrophy.
Serial brain MRIs were available in two siblings (Family
2 Individuals II-1 and II-2) from birth or 2 weeks of age
until the ages of 10 and 5 years, respectively. Of note, in
both siblings, the myelination and CC were normal in the
first 2 months of life but showed marked CC atrophy and
loss of myelination at follow-up brain MRI during the
second year of life with plateauing of myelination and an
apparent static myelin state on brain MRIs obtained fol-
lowing the second year of life (Fig. 1L–Q and S–X). One
of these siblings (Family 2 Individual II-2) had docu-
mented acquired microcephaly with onset of 4 months as
discussed above (Fig. 3A and B). These findings suggest
that the natural course of disease is progressive in the first
2 years of life followed by a static course.
Brain magnetic resonance spectroscopy (MRS) was per-
formed in only one individual (Family 4 individual II-6)
Figure 2. Pedigrees, Sanger sequencing, facial features, and brain MRI images of affected individuals from Families 4–6 with biallelic variants in
GRM7. (A) Pedigree and Sanger sequencing showing segregation of the variants in GRM7 in Family 4. (B) Facial photograph of individual II-1
(Family 4) in first year of life with normal facial features. (C) Facial photograph of individual II-4 (Family 4) at 1 month shows a long philtrum. (D
and E) Brain MRI of individual II-4 (Family 4) at 2 weeks. T1-weighted image (midsagittal view) shows normal cerebrum, CC, and cerebellum (D).
T2-weighted image (axial view) shows under-opercularization of sylvian fissures (more prominent on the left) (E). (F) Facial photograph of
individual II-6 (Family 4) at 4 years with hypotonic face and tented mouth. (G–I) Brain MRI of individual II-6 (Family 4) at 4 years. T1-weighted
image (midsagittal view) shows severe cerebral atrophy, severe thinning of CC, and mild cerebellar atrophy (G). T2-weighted images (axial and
coronal views) show severe cerebral atrophy, severe thinning of CC, and bilateral hippocampal atrophy with right hippocampal hyperintensity (H
and I). (J) Pedigree and Sanger sequencing showing segregation of the variants in GRM7 in Family 5. (K) Facial photograph of individual II-1
(Family 5) at 7 months showing normal facial features. Note that individual II-1 (Family 5) carries a second molecular diagnosis of Klinefelter
syndrome as his chromosomal analysis showed 47,XXY. (L-N) Brain MRI of individual II-1 (Family 5) at 6 months. T1-weighted image (midsagittal
view) shows thin CC (L). T1-wieghted and T2-weighted images (axial views) show simplified gyral pattern (M-N). (O) B-allele frequency for
individual II-1 (Family 5) calculated from exome variant data demonstrates a 2.6 Mb block of AOH on chromosome 3, marked by grey zones, and
show that GRM7 is located within the AOH block. (P) Pedigree and Sanger sequencing showing segregation of the variants in GRM7 in Family 6.
(Q) Facial photograph of individual II-1 (Family 6) at 20 months of age shows upslanted palpebral fissures. (R-T) Brain MRI of individual II-1 (Family
6) at 18 months. T1-weighted image (midsagittal view) shows severe thinning of CC, moderate cerebral atrophy and mild cerebellar atrophy (R).
T2-weighted images (axial and coronal views) show moderate cerebral atrophy, global hypomyelination for age, and under-opercularization of
sylvian fissures (S and T). (U) B-allele frequency for individual II-1 (Family 6) demonstrates that GRM7 is located within a large AOH block (7.3Mb)
on chromosome 3 marked by grey zones.
616 © 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
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and was obtained at 6 months of age revealing a mark-
edly reduced N-acetyl aspartate level and relatively high
choline peak. No glutamate peak was noted. Additionally,
cerebrospinal fluid (CSF), glucose, lactate, and neuro-
transmitter metabolites were performed in two affected
individuals (Family 2 individual II-2 and Family 4 indi-
vidual II-6) and were all within normal limits. One of
these subjects (Family 2 individual II-2) also had a nor-
mal CSF amino acids profile.
EEG findings are summarized in Table 3 with available
EEG traces shown in Figure 3. The majority of the sub-
jects (6/8) had diffuse background slowing indicating
cerebral dysfunction. Epileptiform activity was also pre-
sent in almost all subjects (7/8), with focal or multifocal
epileptiform activity (6/8) seen more frequently than a
generalized slow spike and slow wave pattern (1/8). Sei-
zures captured on EEGs in two subjects included general-
ized myoclonic seizures with generalized electro-
decrement and superimposed paroxysmal fast activity in
one subject, and focal tonic with generalized electro-
decrement in the second subject. The presence of severe
developmental impairment, early-onset seizures and fre-
quent epileptiform activity with background slowing on
EEG in a majority of subjects is consistent with DEE.
Molecular characterization of rare GRM7
biallelic variants
Table 4 contains the summary of the variants observed:
seven variants from six unrelated families that included
five homozygous variants and one family with compound
heterozygous variants. The pedigree diagrams, Sanger
sequencing data and segregation studies of the variants,
and facial morphological features of the affected individu-
als are shown in Figures 1 and 2. mGluR7 protein model
structure, localization of variants and implicated amino
acids, and variant conservation are displayed in Figure 4.
The majority of the identified variants cluster within the
transmembrane domain, except for two variants that are
located at the ligand-binding or intracellular domains
(Fig. 4A and C). All variants were located within highly
conserved regions in vertebrates and higher species
(Fig. 4B and C). In general, subjects with the stop-gain or
missense variants within the transmembrane domain
(Families 2–4 and 6) showed a more severe phenotype
compared to those with missense variants located within
the ligand-binding (Family 1) or intracellular (Family 5)
domains. Compound heterozygous variants were present
in one family (Family 2) with no reported history of con-
sanguinity, while homozygous variants were present in
the other five families (Families 1 and 3–6) with self-re-
ported history of consanguinity (1o cousin marriages). All
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blocks of AOH ranging from 2.6 to 9.7Mb. Total AOH in
these affected individuals ranged from 24.6 to 575Mb
(Table 4). One subject (Family 5 individual II-1) carried
a second molecular diagnosis consistent with Klinefelter
syndrome based on a clinical G-banded chromosomal
analysis showing 47,XXY. The diagnosis of Klinefelter
syndrome in this subject may contribute to the NDD
phenotype but does not fully explain the severe neurolog-
ical features in isolation.
Discussion
We comprehensively characterized the clinical features
and variants in six families with biallelic variants in
GRM7 and showed that rare GRM7 biallelic variants can
cause a severe neurological phenotype characterized by
microcephaly, DEE, hypomyelination, and cerebral atro-
phy. Overall, the findings of both congenital neuroimag-
ing features such as under-opercularization and thin
corpus callosum and progressive features such as cerebral
atrophy suggest that GRM7-related disorders are both
congenital and progressive in nature similar to that seen
in GRIA2-related NDDs.7 Additionally, other disorders
such as CDKL5-related and FOXG1-related disorders
cause a wide and heterogeneous range of NDDs.29,30 It is
possible that the phenotype-first approach of our cohort
has introduced an ascertainment bias toward enrolling
subjects with more severe, and potentially homogenous,
Family 2, Individual II-2
Growth Chart: International/Interracial
Head Circumference-for-age Percentiles (Boys, birth to 2 years) 
Family 2, Individual II-2
Growth Chart: International/Interracial




































0 2 24 46 616 1618 2422208 810 1014 1412 12







DC Family 1, Individual II-1
10-Sec EEG epoch 
(AP Bipolar montage, sensitivity of 15uV/Sec)
Family 6, Individual II-1
10-Sec EEG epoch 
(AP Bipolar montage, sensitivity of 7uV/Sec)
A B
Figure 3. Head circumference charts and EEG epochs. (A) Head circumference-for-age chart (boys, birth to 2 years) of individual II-2 from Family
2 showing normal head circumference at closer to 50th centile with crossing of centiles to less than 2nd centile starting at around 4 months of
age through 14 months of age. The pattern is consistent with an acquired microcephaly. (B) Head circumference-for-age chart (boys, 2–18 years)
of same individual (individual II-2 from Family 2) showing that despite steady head growth, head circumference remains consistently under the
2nd centile from 2 years to 9 years of age. (C) 10-sec epoch from a routine EEG of individual II-1 from Family 1 (anterior–posterior bipolar
montage, sensitivity of 15 lV/Sec) showing diffuse background slowing and multifocal epileptiform activity most prominent at 6–7 sec from start
of epoch. (D) 10-se epoch from a routine EEG of Individual II-1 Family 6 (anterior–posterior bipolar montage, sensitivity of 7 lV/Sec) showing
diffuse background slowing and abundant multifocal epileptiform activity throughout the epoch.
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phenotype. Identification of more cases using a gene-first
approach will likely reveal the entire and broad spectrum
of GRM7-related disorders.31,32
Genotype–phenotype correlation of our limited data
suggests that stop-gain and missense variants affecting the
transmembrane domain result in a more severe pheno-
type compared to missense variants located in ligand-
binding or intracellular domains. We hypothesize that the
reported biallelic variants are loss-of-function (LoF) alle-
les, with the missense variants causing partial LoF (hypo-
morphic) while the stop-gain variants result in complete
LoF (amorphic). Both stop-gain variants identified (Fam-
ily 3 and Family 6) were in exon 8 of total 10 exons in
GRM7. The resultant transcripts with these premature ter-
mination codons will either be degraded by nonsense-me-
diated decay or result in a truncated protein, both of
which are expected to result in complete LoF.33 This LoF
of mGluR7 is expected to result in loss of inhibition in
the glutamatergic pathway, excess glutamate release, and
subsequently hyperexcitability.
Glutamate is an excitatory neurotransmitter that is
robustly implicated in the pathophysiology of epilepsy, a
disorder characterized by aberrant neuronal hyperex-
citability. Excessive and abnormal neuronal firing in sei-
zures leads to depolarization shift, increase in extracellular
glutamate, and subsequent neuronal excitotoxicity.3 This
results in a vicious cycle with aberrant glutamate release
contributing to further epileptogenicity, and seizure main-
tenance and progression.3
Hyperexcitability of the glutamatergic pathway could
lead to the severe epilepsy phenotype as noted in all
affected individuals. All our subjects had the onset of
their seizures in infancy, with seizures starting in the
neonatal period in nearly half of them (Table 2). Addi-
tionally, the significant history of early postnatal apneas
and desaturations requiring NICU admission may suggest
the possibility of missed seizures with earlier onset than
reported in some individuals. Two of our subjects showed
early signs of early hippocampal sclerosis (HS) with hip-
pocampal atrophy and signal abnormality. While it
remains unclear if HS is a cause or a sequela of frequent
seizures, the aberrant expression of mGluR7 in the hip-
pocampus may be a contributing factor.34,35
Excessive glutamate is also neurotoxic, potentially
explaining the marked and early progressive cerebral atro-
phy and axonal loss observed in our subjects, particularly
the affected siblings in Family 2 with the observations of
longitudinal MRI data and the acquired microcephaly
pattern in one of them. Interestingly, postnatal decelera-
tion of head growth has been observed in 5/28 subjects
with deleterious monoallelic variants in GRIA2, a gene
encoding a subunit of another glutamate receptor,
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quantify this finding is limited due to the lack of longitu-
dinal data in other subjects. One caveat is that one of our
subjects (Family 4 individual II-6) had an MRS that did
not show a glutamate peak, but this observation cannot
be generalized either, as it was a one-time observation in
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At the neuronal synapses, glutamate signals through
two groups of receptors, iGluRs and mGluRs. AMPAR is
the most abundant iGluR in the mammalian brain and is
responsible for fast excitatory neurotransmission while
NMDAR is important for slow synaptic potential and
information processing.3 KAR is thought to play a role in
presynaptic and postsynaptic modulation of neurotrans-
mission.36 De novo and inherited pathogenic variations in
genes encoding postsynaptic iGluRs subunits cause a wide
range of NDDs and DEEs.4–10 Interestingly, biochemical
and in vitro functional assays show that variants in the
same gene encoding some NMDAR and AMPAR subunits
(e.g. GRIN2A, GRIN2B, GRIN2D, and GRIA2) may act as
both gain-of-function (GoF) and LoF and may result in
indistinguishable neurological phenotypes.5–7 This alludes
to the complexity of the glutaminergic pathway with both
enhanced and reduced function leading to NDDs and
DEEs. Patho-mechanisms include alterations in any of the
multiple functional parameters including agonist potency,
sensitivity to negative allosteric modulators, channel
opening probability, surface expression, and current
amplitude response.6,7
mGluR7, encoded by GRM7, is the most abundant
CNS mGluR and is only activated by high glutamate and
GABA concentrations due to its low affinity for these
neurotransmitters. This allows it to function as an auto
or hetero-receptor to downregulate further calcium-de-
pendent glutamate release and thus prevent the neuro-
toxic effect of extracellular glutamate accumulation.37
mGluR7 is evolutionarily conserved and is widely dis-
tributed across the CNS including the hippocampus,
hypothalamus, and thalamo-cortical circuitry synapses.35
Activation of mGluR7 produces a cascade of events
starting with the liberation of Gbc subunits to inhibition
of adenylyl cyclase and reduced cAMP production and
ending with the downregulation of voltage-gated calcium
channels (VGCC).38 mGluR7 also interacts with several
intracellular and scaffolding proteins including PKC (pro-
tein kinase C) and PDZ domain-containing protein
PICK1 (protein interacting with C kinase 1), providing
further complexity to the mechanisms by which it
regulates synaptic transmission.39 The mGluR7-PICK
interaction is critical for receptor function, thus raising
the possibility that the intracellular variant (p.Glu891Lys)
in one of our subjects causes disease by disrupting this
PICK-mGlu7 interaction.
Rodent models of mGluR7 and its scaffolding
(PICK1) or interacting proteins (ELFN1) show that
mGluR7 reduced expression or impairment of its func-
tion or recruitment to synaptic sites lead to symptoms
overlapping with NDDs and DEEs. mGluR7-knockout
mice exhibit spontaneous sensory-provoked seizures;
increased seizure vulnerability to two proconvulsant
agents; reduced fear learning; signs of impaired learning,
short-term and spatial memory, and synaptic plasticity;
and dysregulation of the hypothalamic–pituitary–adrenal
(HPA) axis.18,40,41 Of note, HPA axis dysregulation was
present in at least three of our subjects. Additionally,
mice lacking transmembrane protein ELFN1 (extracellu-
lar-leucine-rich repeat fibronectin domain 1) show early
postnatal deficits in recruiting mGluR7 to synaptic site
and display a remarkably similar neurological phenotype
to mGluR7-deficient mice with late-onset sensory-trig-
gered epileptic seizures and motor and behavioral abnor-
malities.42 Furthermore, impaired mGluR7 interaction
with PICK1 by knockin PDZ-recognition binding motif
of mGluR7 or by pharmacological uncoupling in rodent
models results in low seizure threshold to proconvulsive
agents and produces behavioral changes and EEG dis-
charges consistent with absence-like seizures.43,44 These
animal models demonstrate that abnormal mGluR7
expression or function consistently produce an epilepsy
phenotype.
Apart from one subject with a reported favorable
response to rufinamide, we could not assess the response
to each antiepileptic drug (AED) in retrospect, and our
subjects had poor responses to AEDs overall (Table 2).
However, several US Food and Drug administration
(FDA)-approved AEDs that reduce the glutaminergic
pathway hyperexcitability already exist and show potential
for use in such conditions. These AEDs exert their effect
either directly or indirectly and may possess additional
Figure 4. Variant locations on mGluR7 schematic and protein model and their conservation. (A) Schematic diagram of the neuronal synapse
showing the presynaptic location of mGluR7 and the postsynaptic location of the iGluR7 including NMDAR, AMPAR, and KAR. A magnified
illustration of mGluR7 shows that mGluR7s function as constitutional dimers and consist of four regions: N-terminal ligand-binding domain (LBD),
cysteine-rich domain (CRD), transmembrane domain (TMD), and intracellular domain (ICD). The approximate location of the altered amino acid
residues described in this paper is displayed on the mGluR7 on the left. (B) Model protein structure of GRM7. The model structure covers amino
acids from 41 to 849. The locations of the altered amino acids are represented by spheres on the protein cartoon model. I154 is buried on a loop
between highly conserved alpha helices and beta sheets. Amino acid residues R658, R659, and T675 are highly conserved and located on the
same helix of on transmembrane domain, while W586 is less conserved and located on the loop of the transmembrane domain. Note that E891
is not shown here, since the model structure does not include the intracellular region much. (C) Structure of the mGluR7 protein and the position
of the altered amino acid residues (I154T, W586*, R658W/Q, R659*, T675K, and E891K) and the evolutionary conservation of the altered amino
acids is also displayed.
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neuroprotective effect against glutamate excitotoxicity.
Topiramate selectively inhibits the excitatory neurotrans-
mission mediated by KAR and partially depresses
AMPAR-mediated excitatory current.45 Topiramate also
shows a neuroprotective effect against glutamate excito-
toxicity in rodent hippocampal neurons.46 Felbamate
blocks NMDAR particularly at excessive exposure, thus
inhibiting seizure discharges while preserving normal neu-
ronal firing.47 Perampanel is a first-in-class noncompeti-
tive selective AMPAR antagonist that blocks AMPAR by
acting on an allosteric site rather than the glutamate
recognition site.48 Voltage-gated sodium channel blockers
such as lamotrigine, phenytoin, carbamazepine, oxcar-
bazepine, lacosamide, rufinamide, and eslicarbazepine can
also reduce glutamate release indirectly by blocking
sodium-evoked calcium influx.49 Gabapentin and prega-
balin reduce the calcium-dependent glutamate release by
selectively binding at the a2d-1 subunit of VGCC.50 In
addition, cannabinoids, a newly emerging therapy in
treatment of refractory epilepsy, can indirectly modulate
glutaminergic neurotransmission through neuronal
cannabinoid receptor 1 (CB1).51 Whether any of the
above-mentioned AEDs that target the glutaminergic
pathway prove to be particularly effective in treating epi-
lepsy due to deleterious variants in GRM7 is an area for
further investigation.
Additionally, there are ample neuropharmacological
studies focusing on the potential for using allosteric mod-
ulators of mGluRs in the treatment of neurological dis-
eases and epilepsy.52,53 Selective positive allosteric
modulators (PAMs) for group III mGluRs have been
recently developed, potentially representing novel targeted
and personalized therapy in partial mGluR7 LoF (hypo-
morph alleles). PAMs are noncompetitive agonists that
bind to a site other than the ligand-binding site to poten-
tiate their effect.12 N,N0-dibenzhydrylethane-1,2-diamine
dihydrochloride (AMN082) is the first selective mGluR7
PAM to be discovered.54 AMN082 binds to an allosteric
site at the transmembrane domain to fully activate
mGluR7.54 Thus, the potential use of AMN082 would be
predicted to be dependent on the variant location. How-
ever, AMN082 shows scarce selectivity in vivo, off-target
effect, and mixed proconvulsive and anticonvulsive profile
in pentylenetetrazol-treated rats, limiting its potential for
clinical use and underscoring a need for preclinical
in vivo knockout studies.55,56
We show here that rare biallelic variants in GRM7
cause a severe neurological phenotype characterized by
microcephaly, DEE, hypomyelination, and cerebral atro-
phy. Functional studies at the variant level would provide
better insight into the patho-mechanism of the disorder
and evaluate the potential for targeted therapy.
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